Jacob Rubens
Keine laufenden Positionen mehr
Profil
Jacob Rubens is the founder of Quotient Therapeutics Ltd., where he holds the title of President since 2022.
Dr. Rubens is also the founder of Tessera Therapeutics, Inc. Dr. Rubens's current job is as a Senior Principal at Flagship Pioneering since 2015.
Dr. Rubens's education includes an undergraduate degree from Washington University in St. Louis and a doctorate degree from Massachusetts Institute of Technology.
Aktive Positionen von Jacob Rubens
| Unternehmen | Position | Beginn |
|---|---|---|
Flagship Pioneering
 Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Private-Equity-Analyst | 01.01.2015 |
Tessera Therapeutics, Inc.
 Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Gründer | - |
Ausbildung von Jacob Rubens
| Massachusetts Institute of Technology | Doctorate Degree |
| Washington University in St. Louis | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Flagship Pioneering
Flagship Pioneering Investment ManagersFinance Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Tessera Therapeutics, Inc.
Tessera Therapeutics, Inc. BiotechnologyHealth Technology Tessera Therapeutics, Inc. engages in science company. It offers scientists and doctors the ability to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source. The company is headquartered in Cambridge, MA. | Health Technology |
